Exhibit 99.1
Appendix3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited (“Kazia”) |
rsN 37 063 259 754 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Mr lain Ross | |
Date of last notice | 21 December 2021 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest
| Direct | |
Nature of indirect interest (including registered holder)
Note: Provide details of the circumstances giving rise to the relevant interest. | ||
Date of change
| 6 September 2022 | |
No. of securities held prior to change | 1,075,001 ordinary shares
400,000 unlisted options
| |
Class | Ordinary shares | |
Number acquired | 175,000 | |
Number disposed | N/A |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation | 175,000 ordinary shares at $0.2207 per share | |
No. of securities held after change | 1,250,001 ordinary shares
400,000 unlisted options | |
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Purchased on market |
Part 2 - Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of“notifiable interest of a director” should be disclosed in this part.
Detail of contract | ||
Nature of interest | ||
Name of registered holder (if issued securities) | ||
Date of change | ||
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed |
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
Appendix3Y
Change of Director’s Interest Notice
Interest acquired | ||
Interest disposed | ||
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation | ||
Interest after change |
Part 3 - +closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No | |
If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A | |
If prior written clearance was provided, on what date was this provided? |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited (“Kazia”) |
rsN 37 063 259 754 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Steven Coffey | |
Date of last notice | 21 December 2021 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest | Indirect | |
Nature of indirect interest (including registered holder)
Note: Provide details of the circumstances giving rise to the relevant interest. | Fortune 501 Pty Limited (SR Coffey Superfund) Steven Coffey Coffey Family Investments Pty Limited | |
Date of change | 6 & 7 September 2022 | |
No. of securities held prior to change | 426,250 ordinary shares (indirect)
8,015 ordinary shares (direct) 400,000 unlisted options (direct)
50,000 ordinary shares | |
Class | Ordinary shares | |
Number acquired | 50,000 ordinary shares (indirect) | |
Number disposed |
+ See chapter 19 for defined terms.
01/01/20n Appendix 3Y Page 1
Appendix3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
| 73,372 ordinary shares at $0.2097 per share 26,628 ordinary shares at $0.235 per share | |
No. of securities held after change | 426,250 ordinary shares (indirect)
8,015 ordinary shares (direct) 400,000 unlisted options (direct)
100,000 ordinary shares (indirect)
| |
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Purchased on market |
Part 2 - Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract | ||
Nature of interest | ||
Name of registered holder (if issued securities) | ||
Date of change | ||
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed |
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
Appendix3Y
Change of Director’s Interest Notice
Interest acquired | ||
Interest disposed | ||
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation | ||
Interest after change |
Part 3 - +closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No | |
If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A | |
If prior written clearance was provided, on what date was this provided? |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited (“Kazia”) |
rsN 37 063 259 754 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Dr James Garner | |
Date of last notice | 21 December 2021 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest | Direct | |
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | ||
Date of change | 6 & 7 September 2022 | |
No. of securities held prior to change | 500,000 ordinary shares
4,500,000 unlisted options | |
Class | Ordinary shares | |
Number acquired | 100,000 ordinary shares | |
Number disposed | N/A |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation | 50,000 ordinary shares at an average price of $0.2250
50,000 ordinary shares at an average price of $0.2377 | |
No. of securities held after change | 600,000 ordinary shares
4,500,000 unlisted options | |
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Purchased on market |
Part 2 - Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract | ||
Nature of interest | ||
Name of registered holder (if issued securities) | ||
Date of change |
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
Appendix3Y
Change of Director’s Interest Notice
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed | ||
Interest acquired | ||
Interest disposed | ||
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation | ||
Interest after change |
Part 3 - +closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No | |
If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A | |
If prior written clearance was provided, on what date was this provided? |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited (“Kazia”) |
rsN 37 063 259 754 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Mr Bryce Carmine | |
Date of last notice | 21 December 2021 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest | Direct | |
Nature of indirect interest (including registered holder)
Note: Provide details of the circumstances giving rise to the relevant interest. | ||
Date of change | 6 September 2022 | |
No. of securities held prior to change | 419,861 ordinary shares
400,000 unlisted options | |
Class | Ordinary shares | |
Number acquired | 120,000 Ordinary shares | |
Number disposed | N/A |
+ See chapter 19 for defined terms.
01/01/20n Appendix 3Y Page 1
Appendix3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation | 120,000 ordinary shares at $0.235 | |
No. of securities held after change | 539,861 ordinary shares
400,000 unlisted options | |
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Purchased on market |
Part 2 - Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract | ||
Nature of interest | ||
Name of registered holder (if issued securities) | ||
Date of change | ||
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed |
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
Appendix3Y
Change of Director’s Interest Notice
Interest acquired | ||
Interest disposed | ||
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation | ||
Interest after change |
Part 3 - +closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No | |
If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A | |
If prior written clearance was provided, on what date was this provided? |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3